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The pharmocokinetics of the neuromuscular blocking agents atracurium and vecuronium were found to differ little when studied in patients with normal renal function and in those with renal failure (Fahey et al., 1981; Fahey et al., 1984; Bencini et al., 1986) . Indeed, both drugs are suitable for use in anephric patients (Hunter, Jones and Utting, 1984) . However, the evaluation of these drugs in renal failure requires a knowledge of doses required for the induction, as well as the maintenance, of blockade. In addition, possible interactions with the immunosuppressive agents used commonly in association with renal transplantation require clarification.
In patients with end-stage renal failure we have determined the dose-response relations for initial neuromuscular blockade induced by atracurium, vecuronium or pancuronium, as well as the dose requirements for these drugs during continuous infusion. The design of the study conformed with a previous similar study (Gramstad and Lilleaasen, 1982) and an earlier parallel study (Gramstad and Lilleaasen, 1985) , so that we could compare the present results with our previous findings in patients with normal renal function. Interactions with azathioprine were also assessed in the present investigation.
PATIENTS AND METHODS
Thirty patients (nine female) (ASA class III), 18-63 yr, in renal failure and requiring haemodialysis, were investigated during anaesthesia for transplantation of renal grafts from living or cadaver donors. grafts, bilateral nephrectomy preceded the transplantation. Informed consent was obtained before the patients were randomized to receive atracurium, vecuronium or pancuronium. Sampling was stratified with respect to sex, as well as the distribution of brain-dead and living donor transplants, because only recipients of living donor grafts were routinely given azathioprine before and during the operation. Exclusion criteria were: symptoms of neuropathy (assessed by motor dysfunction or impaired skin sensation in an extremity), other neuromuscular disorders, liver disease, more than 20% deviation from normal weight, peripheral oedema, treatment with aminoglycoside or imidazol antibiotics, preoperative serum calcium concentrations less than 1.9 or greater than 2.9 mmol litre" 1 (normal 2.2-2.6 mmol litre" 1 ), pre-or peroperative serum potassium concentrations of less than 3 or greater than 6 mmol litre" 1 (normal 3.8-4.6 mmol litre" 1 ). Patients excluded because their serum potassium concentration exceeded this predetermined range during surgery were replaced by new patients.
Patients receiving living donor grafts were dialysed 48 h before operation. Recipients of a cadaver graft were transplanted irrespective of day of last dialysis, although six patients required a short period of dialysis before operation to correct hyperkalaemia.
Serum electrolyte concentrations and blood-gas tensions were determined within a few hours before the induction of anaesthesia. Preoperative serum concentrations of magnesium and ionized calcium were measured after storage of frozen samples ( -70 °C). The Ca 2+ concentrations were adjusted to pH 7.40 (ICA 1; Radiometer, Copenhagen).
Patients scheduled to receive living donor transplants were given azathioprine 5 mg kg" 1 by mouth on each of the 2 days preceding operation. Premedication was with diazepam 10 mg by mouth about 2 h before operation. Patients with metabolic acidosis, which might have required correction during the early stage of surgery, were given 4.2 % sodium bicarbonate before the induction of anaesthesia.
After the injection of atropine 0.6 mg i.v., anaesthesia was induced with diazepam 15-30 mg, fentanyl 0.1-0.5 mg, and sufficient thiopentone 0-325 mg i.v. to abolish the eyelash reflex. Ventilation was assisted with 100% oxygen via a face mask. The ulnar nerve of the arm without an arteriovenous shunt or fistula was stimulated electrically at the wrist via subcutaneous needle electrodes which were connected to a Myotest nerve stimulator (Biometer, Odense, Denmark) delivering supramaximal impulses at 0.1 Hz. The evoked adduction force of the thumb was measured using a Statham UC3 transducer (with UL4-20 load cell) connected to a Hewlett-Packard BRITISH JOURNAL OF ANAESTHESIA 7702B recorder equipped with 8805C amplifier. Resting thumb tension was maintained between 200 and 300 g.
When control twitch height was stable, the appropriate neuromuscular blocking drug was given in a cumulative manner. Pilot studies indicated, however, that a cumulative technique required more time in uraemic patients than in comparative groups of normal patients (previously investigated using four cumulative doses (Gramstad and Lilleaasen, 1982) ). Therefore, we gave four equal increments, the two first increments administered in one dose, to produce up to three points on each individual dose-response curve. After the injection of each dose, the twitch response was observed until a maximum effect was obtained, as judged by three consecutive twitches of equal height, before the next dose was given. The total dose was equal to the ED B6 estimated previously in normal patients using a comparable cumulative technique (Gramstad and Lilleaasen, 1982) . The increments were: atracurium 69 ug kg" 1 , vecuronium 14 ug kg" 1 and pancuronium 16 (J.g kg" 1 .
At maximum effect, and after the last incremental dose, the trachea was intubated. In poor responders, however, an additional dose producing about 90-95% twitch depression was given before intubation. Subsequently, ventilation was controlled mechanically (Servo 900B ventilator). Anaesthesia was maintained with 60-65 % nitrous oxide in oxygen, and increments of fentanyl were given as required. The inspired minute volume was adjusted, either to keep end-tidal carbon dioxide concentration between 4 and 5 vol % (Siemens-Elema CO, Analyzer 930 connected to the ventilator), or to keep arterial carbon dioxide tension between 4.0 and 5.3 kPa (ABL3 blood gas analyser (Radiometer, Copenhagen)). A heating mattress was used to prevent cooling during operation.
After the maximum effect of the last increment of the neuromuscular blocker had been obtained, the drug was administered by continuous infusion, using a Hoechst PP50 infusion pump. The drug solutions were prepared in physiological saline at 4 °C immediately before anaesthesia. Concentrations of the solutions were chosen so that the 50-ml infusion syringe should not normally have to be replaced during the study. The concentrations were: atracurium 1.8 mg ml" 1 , vecuronium 0.4 mg ml" The rate of infusion was titrated to produce constant 90 % twitch depression. After 60 min of neuromuscular blockade the infusion rate was held constant, and the drug requirements and the twitch responses registered. After a subsequent 15-min period with constant-rate infusion, the twitch response was remeasured, and the individual changes in response during the 15-min time interval were noted.
Azathioprine 3 mg kg" 1 was then administered at the rate of 1 mg kg" 1 min" 1 , while the infusion rate of the neuromuscular blocker was held constant. The ensuing maximum interaction and its latency, as well as twitch response 10 min after the end of the azathioprine administration were measured. In patients receiving living donor grafts, prednisolone 100 mg was given subsequently as a bolus injection and the twitch response was registered for a further 15 min. In recipients of cadaver donor grafts, the injection of prednisolone 100 mg preceded the administration of azathioprine by 0.5 min, because of the more rapid surgery in these patients.
Infusions of 0.9% sodium chloride, Ringer's acetate solution and 5% glucose were administered during the recordings. No blood products were given during the period of the study. The investigations were completed in all patients before the administration of frusemide and the declamping of the renal artery.
The observed twitch depressions were probit transformed for statistical evaluation (Finney, 1952) and log transformations were used in the analysis of drug doses. Composite dose-response curves for initial neuromuscular blockade were determined by a weighted variance component analysis of individual regressions. A preliminary test of our infusion and interaction measurements using a goodness-of-fit test (Shapiro and Wilk, 1965) showed that the approximation to a Gaussian distribution was not rejected (P = 0.05), therefore parametric statistical tests were used. Differences between groups were analysed by Student's t test when appropriate, or analysis of variance followed by Bonferroni's t test. Differences were considered statistically significant if P < 0.05.
RESULTS
Biochemical values and anthropometric data were comparable in the three groups of patients (table  I) . New patients replaced two patients who were excluded because their preoperative serum potassium concentrations (mmol litre" 1 ) of 5.0 and 5.3 increased to 6.6 during the study. Cadaver grafts were used in 21 patients; nine patients received a graft from a living donor. Sixteen patients suffered from chronic glomerulonephritis. Other causes of renal failure included chronic pyelonephritis (four), unspecified nephritis (three), diabetic nephropathy (three) and other diseases (four). Nine patients had received frusemide more than 12 h before operation. Half the patients were on treatment with one or more anti-hypertensive drugs (mainly beta-blocking agents and prazosin). The majority were receiving preparations of iron, vitamins and antacids. A retention enema of calcium polystyrene sulphonate 30 g was required before anaesthesia in one patient in the atracurium group and two patients in the vecuronium group.
An earlier parallel study had demonstrated no evidence of a sex difference in sensitivity to neuromuscular blockers (Gramstad and Lilleaasen, 1985) . In the present study, preliminary analysis of the interactive effects of azathioprine demonstrated negligible effects on neuromuscular blockade. The stratification factors were, therefore, ignored in the subsequent statistical analysis.
Initial neuromuscular blockade
Individual dose-response curves are shown in figure 1 and the calculated dose-response values are presented in table II. Relative potencies for atracurium, vecuronium and pancuronium were 1:5.5:3.9 (ED 60 ) and 1:5.6:4.3 (ED 85 ). The periods between first and last cumulative doses were (mean± SD): atracurium 9.0 min±0.9, vecu- (Gramstad and Lilleaasen, 1982) . The periods between first and last cumulative dose in these latter patients were (mean±SD): atracurium 9.6 min ±1.3, vecuronium 9.7 min ±1.4, and pancuronium 10.4 min±2.5. These times are similar to those of the present investigation, making these studies comparable. Our findings show that 20-45 % larger thnn normal ED M initial doses of the neuromuscular blockers are required in patients with end-stage renal failure (table II) .
Infusion administration
Practically stable infusion-response conditions were obtained in all patients before we tested the change in response at constant-rate infusion for 15-min period. Figure 2 shows the distribution of responses at each end of this time interval. The individual changes in response between the beginning and the end of this period were, in absolute values (median with total range in 10" 1 probits): atracurium 11 (5-20), vecuronium 3 (0-30) and pancuronium 9 (0-14). The drug requirements during the constant rate infusionresponse interval are presented in table III. The table shows that the relative potency of atracurium and vecuronium for the maintenance of neuromuscular blockade in end-stage renal failure (1:5.2) approximates the potency ratio observed in relation to the initial neuromuscular blockade. Table III also gives the drug requirements during similar conditions in patients without renal failure, obtained from a parallel study (Gramstad and Lilleaasen, 1985) . The present study started about 3 months before, and was completed about 6 months after, the parallel study in normal patients. Dose requirements for sustained 90% blockade were reduced in end-stage renal failure by 20% for vecuronium and 57% for pancuronium. The maintenance dose of atracurium was not markedly influenced by renal function. Two patients were excluded from this latter part of the study: one patient in the pancuronium group (brief obstruction of the infusion line) and one patient in the atracurium group (peroperative infusion of cyclosporin, which might have potentiated neuromuscular blockade) (Gramstad et al., 1986) ).
Azathioprine interaction
The injection of azathioprine 3 mg kg" 1 caused a rapid, but small and transient decrease of neuromuscular blockade ( fig. 2, table IV) . Mean degrees of blockade before the injection of azathioprine, and at maximum antagonism, were: atracurium 91.4-89.1%, vecuronium 90.5-87.3%, and pancuronium 88.4-82.6%. The differences between atracurium and pancuronium reached statistical significance. Ten minutes after the end of the injection of azathioprine, residual interaction was detectable in the pancuronium group only.
In the nine patients receiving living donor grafts, the injection of prednisolone 100 mg 10 min after the administration of the azathioprine produced no apparent change in neuromuscular blockade during a subsequent 11-15-min observation period. To test a possible overall difference in azathioprine interaction between patients with and without prednisolone, the Wilcoxon test statistic for each drug group was calculated (Lehmann, 1975) . By addition of x* statistics (Armitage, 1980 ) the estimated value of P was 0.57.
DISCUSSION
Estimations of the dose-response relations for neuromuscular blocking drugs in patients in renal failure pose particular problems, because the pathophysiological manifestations of the disease are heterogeneous in uraemic patients. Strict criteria for eligibility were, therefore, used to obtain a fairly homogeneous group of patients in relatively uncomplicated end-stage renal failure.
Exclusion criteria which included serum potassium concentrations substantially different from normal were deemed necessary, because it is our experience that the serum potassium concentration may fluctuate considerably during anaesthesia in such patients. For example, in one patient in the pilot study in whom serum potassium concentration decreased to 2.2 mmol from a preoperative value of 3.9 mmol, neuromuscular blockade remained virtually unchanged for about 40 min after the discontinuation of an infusion of pancuronium.
Individual dose-response curves showed great variation in response to the neuromuscular blocking drugs in renal failure. Vecuronium was found to be 5.5-5.6 times more potent than atracurium and 1.4-1.3 times more potent than pancuronium for ED 50 and ED, 6 doses. These relative doses compare well with our previous findings in normal patients, showing vecuronium to be about 5 times more potent than atracurium and about 1.2 times more potent than pancuronium (Gramstad and Lilleaasen, 1982) . However, the absolute dose requirements for the initial induction of neuromuscular blockade were significantly increased in end-stage renal failure-by 37% (atracurium), 20% (vecuronium), and 45% (pancuronium). Since estimations of ED 85 values are, to a great extent, based on linear extrapolations of dose-response relations, the ED 60 values were compared rather than the ED 8a values, even though the latter are more important clinically.
A decrease in the response of atracurium in renal failure was reported recently by Nguyen and colleagues (1985) . Using a divided dose of 325 ug kg" 1 during train-of-four stimulation, these workers found 98% depression of twitch height in normal patients and 93.9% in anephric patients, the latter finding comparing with our ED M value of 375.6 ug kg" 1 . Previous investigations have not demonstrated significant differences in responses of vecuronium between patients with normal and those with failure of renal function (Meistelman et al., 1983; Bevan et al., 1984; Orko, Heino and Rosenberg, 1985) ; although Hunter, Jones and Utting (1984) reported two anephric patients who were highly resistant to vecuronium. Apparent tolerance to vecuronium in renal failure was found by Bencini and colleagues (1986) who measured significantly higher plasma concentrations at 25 and 75% recovery in anephric patients than in patients without renal failure.
To our knowledge, the dose-response relation for pancuronium in patients in renal failure has not been published previously. By using pharmacokinetic-dynamic modelling, Hull and coworkers (1978) demonstrated that patients with total renal failure are likely to be marginally resistant to small doses of pancuronium. These calculations were based on estimated variables by McLeod, Watson and Rawlins (1976) , who found that the distribution parameters of pancuronium were altered significantly in renal failure. However, other investigators have not found such differences in the distribution kinetics of pancuronium between patients with normal and failing kidney function (Somogyi, Shanks and Triggs, 1977; Buzello and Agoston, 1978) .
As discussed by Feldman (1979) , the neuromuscular blocking agent will distribute rapidly into the extracellular water, and the blockade produced will depend on the peak drug concentration in this fluid. The extracellular fluid volume is increased in patients with chronic renal failure requiring regular haemodialysis (Mitch and Wilcox, 1982) . In similar patients at our hospital the extracellular fluid volume (sulphate space) was 30.6% larger than normal controls, when measured 48-72 h after dialysis (Fauchald, 1986) . Thus such alteration in the distribution of body fluids may increase the dose required for the initial production of neuromuscular blockade in endstage renal failure. It follows that differences in the estimation of potency, as well as pharmacokinetic measurements, in different studies may depend on the state of hydration of the patients in renal failure. In different units patients may be dialysed to different extents toward their "dry weight" (the minimum weight a patient has achieved without causing symptomatic hypotension).
The biochemical and other characteristics of our patients did not provide any evidence of pharmacodynamic reasons for the lower potencies of the neuromuscular blocking agents in renal failure. However, we could hypothesize that there could be alterations in the plasma concentrationresponse relations for the three drugs in end-stage renal failure.
Initial doses giving about 90-95% blockade, followed by a continuous infusion titrated to maintain constant 90 % response, produced stable neuromuscular blockade at fixed infusion rate within 1 h. This corresponds with the constant infusion-response conditions which pertained in our parallel study in patients with normal renal function (Gramstad and Lilleaasen, 1985) . Consequently, the two studies should be directly comparable.
Mean infusion rates for 90 % sustained response were (ug kg" 1 h" 1 ): atracurium 409.4, vecuronium 78.3, and pancuronium 14.2. To our knowledge, infusion dose-response relations for these drugs in renal failure have not been published previously. Compared with the patients with normal renal function, the atracurium requirements were not influenced by the renal failure, whereas the requirements for vecuronium and pancuronium were reduced by 23.2% and 61.5%, respectively.
The clearance of atracurium is not significantly dependent on renal function (Fahey et al., 1984; de Bros et al., 1985) , and this supports our finding, because the infusion rate is directly proportional to drug clearance at steady-state. It also accords with the observation of Hunter, Jones and Utting (1982) that dosing intervals for atracurium increments during prolonged neuromuscular blockade were not affected by absence of renal function.
The clearance of vecuronium has not been demonstrated to decrease significantly in renal failure (Fahey et al., 1981; Bencini et al., 1986) . Nevertheless, about 20 % of the injected dose is excreted in the urine in normal patients (Bencini et al., 1986) , which corresponds to the 23.2% reduction in dose requirement for sustained blockade in the renal failure patients. When using repeated increments of vecuronium to maintain neuromuscular blockade in renal failure, Hunter, Jones and Utting (1984) found no difference in dosing intervals in patients with and without renal failure, whereas Bevan and colleagues (1984) reported significantly longer durations of action after repeated doses in renal failure; the latter view accords with our findings.
If we assume steady-state conditions during the constant-rate infusions with pancuronium, the decrease in dosage in renal failure (61.5%) corresponds with other estimates of decreases in plasma clearance as a result of absent renal function: 69.6% (McLeod, Watson and Rawlins, 1976) and 49.8% (Somogyi, Shanks and Triggs, 1977) .
The interaction of azathioprine with the three neuromuscular blocking agents was minimal and transient. There was no indication that the interaction was modified by the preinjection of prednisolone; neither did this steroid affect neuromuscular blockade when injected 10 min after azathioprine. The lesser interaction with atracurium than with pancuronium might be explained by the less stable blockade in the former group before the injection of the azathioprine ( fig. 2) .
Antagonistic effects of azathioprine on nondepolarizing neuromuscular blockade in man and cat were previously reported by Dretchen and co-workers (1976) . They showed that neuromuscular blockade with tubocurarine, gallamine or pancuronium in the cat could be completely reversed by the subsequent administration of azathioprine when both drugs were injected to the artery supplying the muscle. The suggested mode of interaction was inhibition of phosphodiesterase by azathioprine, causing increased presynaptic release of acetylcholine. In another study in cats azathioprine 1 or 5 mg kg" 1 i.v. caused no interaction when injected at maximum blockade after a single bolus dose of atracurium (Chappie, Clark and Hughes, 1983) .
These seemingly discrepant findings can probably be explained by the different experimental conditions. Approximated steady-state conditions in our study would provide a more sensitive method than using single bolus injections. When using i.a. injection of the neuromuscular blocker, the concentration gradient from the active site is large after maximum response, and the competitive non-depolarizing drug can rapidly diffuse away when acethylcholine release is facilitated transiently. Measurements during stable blockade in the present study showed minimal interactions, demonstrating that the antagonism produced by azathioprine was clinically negligible during the continuous infusion of neuromuscular blocking drugs.
